SecBot SecBot
PRESS-RELEASE ·Filed May 20, 2026

PCRX

Pacira BioSciences
MIXED
Impact 7/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight ◆ Mixed

The proxy fight outcome is binary: a DOMA win could trigger a sale process or cost cuts, while a Pacira win maintains current strategy. The cross-filing amplifier suggests this activist context increases expected stock movement. Monitor vote tallies and any further 13D filings from DOMA. The June 9 meeting date is the key catalyst.

DirectionMixed
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK AT ENTRY AT T+60
Entry
$23.00
T+0 close · May 20, 2026 · via day close
Latest settled
0.00%
T+60 · $23.00
Vs SPY
−5.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 20 $23.00entry
  2. T+1 · 6mo ago +2.09%α +1.89% · $23.48
  3. T+5 · 6mo ago +2.96%α +1.15% · $23.68
  4. T+20 · 5mo ago −2.91%α −3.65% · $22.33
  5. T+60 · 3mo ago 0.00%α −5.00% · $23.00

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pacira BioSciences issued a press release urging stockholders to vote for its board nominees at the June 9 annual meeting, countering activist DOMA Perpetual Capital Management. The company highlighted record 2025 revenue of $726.4M, 79.4% GAAP gross margins, and a $200M buyback return since April 2025, while criticizing DOMA's plan to cut costs, halt pipeline development, and pursue a sale. This is an escalating proxy fight with material implications for strategic direction.

Key Financial Metrics

Revenue
$726.4M

Key Facts

  • Pacira achieved record total revenue of $726.4M in 2025 with GAAP gross margins of 79.4% and non-GAAP gross margins of 81.2%.
  • Q1 2026 revenue: EXPAREL $143.3M (+5% YoY), ZILRETTA $26.8M (+15% YoY), iovera° $6.2M (+21% YoY).
  • Company has returned $200M to stockholders since April 2025 under a $300M share repurchase program.
  • Pacira reached a volume-limited settlement in EXPAREL patent litigation securing exclusivity through 2030.
  • Activist DOMA Perpetual Capital Management seeks to replace three directors, cut costs, discontinue pipeline, replace CEO, and initiate a sale process.
  • Annual meeting scheduled for June 9, 2026; record date April 22, 2026.
  • Pacira's board would be 89% independent with average tenure of ~4.6 years after the meeting.
  • Cross-filing context: press-8k-context + press-activist-context is an amplifier (PMI=2.28, q=0.000, n=3144).

Financial Impact

Record revenue of $726.4M in 2025; Q1 2026 revenue growth across all three products (5-21% YoY); $200M returned via buybacks; $300M buyback program authorized.

revenuegross marginshare repurchasepipeline investment

Risk Factors

  • Activist victory could lead to a fire sale at potentially depressed valuation.
  • DOMA's proposed cost cuts may harm revenue growth and pipeline prospects.
  • Patent litigation settlement is volume-limited, leaving some uncertainty on exclusivity beyond 2030.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3298294

Track record

29 reports on PCRX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 20, 2026